Genmab A/S News Releases https://ir.genmab.com/ Genmab A/S News Releases en Major Shareholder Announcement https://ir.genmab.com/news-releases/news-release-details/major-shareholder-announcement-37 Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 18, 2019, BlackRock, Inc. Wed, 19 Jun 2019 11:35:42 -0400 Genmab A/S News Releases 36626 Major Shareholder Announcement https://ir.genmab.com/news-releases/news-release-details/major-shareholder-announcement-36 Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; June 19, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 14, 2019, BlackRock, Inc. Wed, 19 Jun 2019 07:57:32 -0400 Genmab A/S News Releases 36616 Genmab A/S has published its Articles of Association https://ir.genmab.com/news-releases/news-release-details/genmab-has-published-its-articles-association-14 Genmab A/S has published its Articles of Association dated June 6, 2019. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm                            Contact:           Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 Thu, 13 Jun 2019 16:41:55 -0400 Genmab A/S News Releases 36596 Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38 https://ir.genmab.com/news-releases/news-release-details/genmab-signs-agreement-janssen-next-generation-cd38-antibody Company Announcement Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody ® -CD38, incorporating Genmab’s proprietary HexaBody technology New agreement builds on Genmab’s successful DARZALEX ® collaboration with Janssen Tue, 11 Jun 2019 01:48:03 -0400 Genmab A/S News Releases 36581 Grant of Restricted Stock Units and Warrants to Employees in Genmab https://ir.genmab.com/news-releases/news-release-details/grant-restricted-stock-units-and-warrants-employees-genmab-1 Company Announcement Copenhagen, Denmark; June 6, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,464 restricted stock units and 21,343 warrants to employees of the company and three of the company's subsidiaries. Thu, 06 Jun 2019 16:38:40 -0400 Genmab A/S News Releases 36561 U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma https://ir.genmab.com/news-releases/news-release-details/us-fda-grants-priority-review-daratumumab-combination-bortezomib Company Announcement U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant September 26, 2019 PDUFA date Copenhagen, Thu, 30 May 2019 17:07:31 -0400 Genmab A/S News Releases 36551 Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq https://ir.genmab.com/news-releases/news-release-details/genmab-files-registration-statement-united-states-proposed Company Announcement Genmab has today filed a registration statement with the U.S. Securities and Exchange Commission for the proposed public offering of ADSs and has applied for listing of the ADSs on the Nasdaq Global Select Market under the symbol “GMAB”                Copenhagen, Denmark; May Tue, 28 May 2019 16:32:20 -0400 Genmab A/S News Releases 36541 Genmab Announces Data to be Presented at 24th EHA Annual Congress https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-24th-eha-annual-congress Media Release Copenhagen, Denmark, May 16, 2019 15 industry-sponsored abstracts featuring Genmab programs selected for presentation at EHA Annual Congress Genmab A/S (Nasdaq Copenhagen: GEN) announced today that 15 industry sponsored abstracts regarding Genmab programs were accepted for Thu, 16 May 2019 09:42:40 -0400 Genmab A/S News Releases 36521 Genmab A/S has published its Articles of Association https://ir.genmab.com/news-releases/news-release-details/genmab-has-published-its-articles-association-13 Genmab A/S has published its Articles of Association dated May 14, 2019. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm                            Contact:           Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 Wed, 15 May 2019 08:37:09 -0400 Genmab A/S News Releases 36501 Capital Increase in Genmab as a Result of Employee Warrant Exercise https://ir.genmab.com/news-releases/news-release-details/capital-increase-genmab-result-employee-warrant-exercise-49 Company Announcement Copenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or Tue, 14 May 2019 15:37:15 -0400 Genmab A/S News Releases 36481